← Back to patent-cliff list
Kamuvudine-9
Tier C — Watch / tradeKamuvudine-9
Inflammasome Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Diabetic macular oedema, 甲状腺相关性眼病
Regional status
US
Phase II
2026-02-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Kamuvudine-9?
Approved indications include: Diabetic macular oedema, 甲状腺相关性眼病.
When does the Kamuvudine-9 patent expire?
No public expiry year is available for Kamuvudine-9 yet; this page updates once verified.
How do I get a quote for Kamuvudine-9 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29